Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07662655

Percutaneous Pulmonary Artery Denervation (PADN) for the Treatment of Pulmonary Hypertension After Transcatheter Mitral Valve Edge-to-Edge Repair (M-TEER): A Prospective Cohort Study

this study aims to investigate the efficacy and safety of PADN therapy compared with standard medical therapy in patients diagnosed with pulmonary hypertension after M-TEER, thereby providing evidence for clinical treatment decision-making

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Pulmonary Hypertension Cardiovascular Diseases Hypertension Hypertension, Pulmonary Lung Diseases Pulmonary Hypertension Associated With HFpEF Respiratory Tract Diseases Vascular Diseases

Age range

18 year–80 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Early Phase 1

Primary location

Structural Heart Disease Unit, Xiamen Cardiovacular Hospital

Xiamen, Fujian, 361000, China

Location status: Recruiting

Location contact

Xiang Chen

CONTACT

[email protected]

18033997788

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age ≥18 years and ≤80 years;
  • Diagnosed with pulmonary hypertension (defined as mPAP >20 mmHg measured by right heart catheterization) at least 3 months after successful M-TEER, having received guideline-directed medical therapy (GDMT) for at least 2 months;
  • No contraindications for PADN (e.g., anatomical abnormalities of the main pulmonary artery precluding catheter placement, known pulmonary artery stenosis, uncontrolled severe arrhythmias);
  • Understands and is willing to sign the informed consent form and authorizes the use of health and study-related information;
  • Willing to comply with the treatment and follow-up schedule required by the protocol

Exclusion criteria

  • Cardiac index (CI) < 1.5 L/min/m²;
  • Severe renal insufficiency (creatinine clearance rate (CrCL) < 30 mL/min);
  • Left ventricular ejection fraction (EF) <30% on echocardiography;
  • Severe hematological disease or severe bleeding tendency (platelet count <10×10⁹/L; severe and extensive bleeding; suspected or confirmed intracranial hemorrhage);
  • Systemic inflammatory disease, malignancy, tricuspid valve stenosis, pulmonary artery stenosis, and other cardiac diseases requiring surgical or interventional treatment;
  • Acute systemic infectious disease;
  • Poor general condition due to various systemic diseases;
  • Pulmonary veno-occlusive disease;
  • Cachexia;
  • Diagnosed with WHO Group 1, 3, 4, or 5 pulmonary hypertension;
  • Anticipated to undergo other surgical or interventional procedures within 6 months;
  • Life expectancy <12 months;
  • Allergy to the drugs or metal materials used in the study;
  • Women who are breastfeeding, pregnant, or planning to become pregnant within one year;
  • Participation in another drug or medical device clinical trial within 3 months prior to screening;
  • Any condition deemed unsuitable for participation in this clinical trial by the investigator. |

Treatment and study plan

Percutaneous Pulmonary Artery Denervation (PADN)

Device

**PADN Procedure Steps:**

  • Non-Selective Pulmonary Artery Angiography
  • PADN Ablation Target Selection
  • Hemodynamic Assessment
  • Establishment of the PADN® RF Catheter Delivery Rail
  • PADN® RF Catheter Delivery
  • Performance of the PADN Procedure While maintaining the transseptal sheath position unchanged, the PADN® RF catheter is gently and slowly withdrawn and rotated (either clockwise or counterclockwise) to bring any three of the No. 2-9 electrodes into close apposition with the three target ablation points A, B, and C. . Temperature-controlled mode is recommended for radiofrequency ablation, with the ablation temperature set to 50°C and the total ablation time set to 150 seconds. The pulmonary artery radiofrequency ablation generator will automatically start calculating the effective ablation time (ET) once the ablation temperature reaches 45°C. Ablation at each target point is considered effective when the ET reaches at least 120 seconds.
  • Completion of the PADN

Control group (receiving standard medical therapy alone)

Drug

Control group (receiving standard medical therapy alone)

Primary outcomes

  1. Clinical worsening event

    Time frame: From enrollment up to 12 months

    defined as the occurrence of any of the following:

    • Worsening heart failure symptoms requiring intravenous therapy (inotropes, diuretics, or vasodilators);
    • Heart failure-related rehospitalization;
    • Decrease in 6MWD from baseline by >10% or >30 meters;
    • Need for heart/lung transplantation;
    • All-cause death

Secondary outcomes

  1. Changes from baseline in pulmonary vascular resistance (right heart catheterization)

    Time frame: From enrollment up to 12 months

    Changes from baseline in pulmonary vascular resistance (PVR); Unit of measure: Wood units

  2. Changes from baseline in echocardiographic linear dimension parameters

    Time frame: From enrollment up to 12 months

    Changes from baseline in right atrial diameter (RAD), left atrial diameter (LAD), left ventricular internal diameter at end-diastole (LVIDd), left ventricular posterior wall thickness at end-systole (LVPWd), and tricuspid annular plane systolic excursion (TAPSE); Unit of measure: millimeters (mm)

  3. Changes from baseline in echocardiographic percentage functional indices

    Time frame: From enrollment up to 12 months

    • Parameters: Ejection fraction (EF), right ventricular fractional area change (RV-FAC)
    • Unit of measure: percentage (%)

  4. Changes from baseline in cardiac output (right heart catheterization)

    Time frame: From enrollment up to 12 months

    • Parameter: Cardiac output (CO)
    • Unit of measure: liters per minute (L/min)

  5. Changes from baseline in WHO functional class

    Time frame: From enrollment up to 12 months

  6. Changes from baseline in NT-proBNP/BNP

    Time frame: From enrollment up to 12 months

  7. Changes from baseline in 6-minute walk distance (6MWD)

    Time frame: From enrollment up to 12 months

  8. Changes from baseline in Short Form-36 (SF-36) Health Survey scale score

    Time frame: From enrollment up to 12 months

    The SF-36 scale ranges from 0 to 100, where higher scores indicate a better outcome (Minimum = 0, Maximum = 100).

  9. All-cause rehospitalization rate

    Time frame: From enrollment up to 12 months

  10. Incidence of worsening heart failure symptoms requiring intravenous therapy

    Time frame: From enrollment up to 12 months

  11. Heart failure-related rehospitalization rate

    Time frame: From enrollment up to 12 months

  12. Rate of need for heart/lung transplantation

    Time frame: From enrollment up to 12 months

  13. Changes from baseline in intracardiac pressure parameters (right heart catheterization)

    Time frame: From enrollment up to 12 months

    • Parameters: mean right atrial pressure (mRAP), right ventricular systolic pressure (RVSP), pulmonary artery systolic pressure (PASP), pulmonary artery diastolic pressure (PADP), mean pulmonary artery pressure (mPAP), pulmonary artery wedge pressure (PAWP)
    • Unit of measure: millimeters of mercury (mmHg)

  14. Changes from baseline in cardiac index (right heart catheterization)

    Time frame: From enrollment up to 12 months

    • Parameter: Cardiac index (CI)
    • Unit of measure: liters per minute per square meter (L/min/m²)

  15. Changes from baseline in pulmonary arterial compliance (right heart catheterization)

    Time frame: From enrollment up to 12 months

    • Parameter: Pulmonary arterial compliance (PAC)
    • Unit of measure: milliliters per millimeter of mercury (mL/mmHg)

Study contacts

Contact information is provided by the study sponsor or research team.

Xiang CHEN, Dr

CONTACT

[email protected]

+8618033997788

Sponsors and collaborators

Lead sponsor

Xiamen Cardiovascular Hospital, Xiamen University

Other

Registry information

Important dates

Study start
2026
Primary completion
2028
Study completion
2028
First posted
Jun 23, 2026
Registry last updated
Jun 23, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.